Nanobiotix Announces Launch of Nanotechnology Platform
NANOBIOTIX recently announced the launch of new subsidiary Curadigm, dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry. The company will be a wholly owned subsidiary of Nanobiotix and operate in France and in the US with a dedicated team committed to growth and potential financing opportunities.
For most therapeutics today, only a small portion of the medicine administered is effective and the rest is cleared from the body without effect or may even be toxic. After injection, the dose moves through the circulatory system within the blood, and while a small portion reaches the targeted tissue the remainder is cleared or accumulates in organs such as the liver.
Curadigm technology aims to change this balance through proprietary “Nanoprimer” technology. Leveraging over 15 years of experience in the development of nanotechnology at Nanobiotix, the company has created nano-scale objects that prime the body for treatment. These nanoparticles, called nanoprimers, have been designed with specific physico-chemical properties that allow them to transiently occupy the liver cells responsible for therapeutic clearance. Injected prior to the therapeutic, the nanoprimer increases systemic bioavailability allowing for increased accrual in the target tissue and therapeutic action.
Curadigm technology shows potential to have broad implications across the healthcare system through its opportunity to increase the efficacy of therapeutics at their current dose, lower the necessary dose thereby decreasing toxicity and cost, and allow for novel therapeutic approaches (eg, new approaches to drug design). In Vivo data proving the concept was published by Nanobiotix in Scientific Reports1 and presented at AACR2019.
Curadigm will be led by Dr. Matthieu Germain, who holds deep expertise in the development of nanoparticles after more than 15 years with Nanobiotix, including initial development of the new technology. Dr. Kate Rochlin, leveraging her strong background in early stage company growth, will join the company as Director of Business Development. Under their leadership, Curadigm will maintain the same core values and spirit of its parent company to significantly improve outcomes for millions of patients through a disruptive approach for therapeutics across healthcare.
Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.
The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.
Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris. The company’s headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in Spain and Germany.
Curadigm, a wholly owned subsidiary of Nanobiotix S.A., will be incorporated this year in France and will aim to expand treatment benefits by increasing drug bioavailability while decreasing unintended off-target effects, specifically liver and spleen toxicities.
The Curadigm platform is being developed for use across multiple therapeutic classes to utilize biocompatible nanoparticles to transiently occupy the pathway responsible for therapeutic clearance and hepatic toxicity.
The Curadigm platform is dedicated to bringing broadly applicable delivery technologies to patients to increase efficacy in both current & novel therapeutics and improve patient outcomes.
Total Page Views: 494